FDA Approves Capivasertib with Abiraterone and Prednisone for PTEN-deficient Androgen Pathway Modulation-Naïve or -Sensitive Prostate Cancer By Ogkologos - July 15, 2026 86 0 Facebook Twitter Google+ Pinterest WhatsApp It also approved a companion diagnostic device Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Coffee Shop Owner Learns He Has Terminal Cancer – So Competitor... February 11, 2020 FDA Expands Indications for Lutetium Lu 177 Vipivotide Tetraxetan to Include... April 25, 2025 Meteorologist Uses Sign Language To Tell All Of Her Weather Forecasts February 12, 2022 Join the Great American Smokeout for a Healthier Tomorrow November 14, 2023 Load more HOT NEWS Breast Cancer Survivors Are Still Underrepresented At Victoria’s Secret EMA Recommends Extension of Therapeutic Indications for Osimertinib Firefighters Band Together To Raise $30k For Breast Cancer Research &... Doctor Said Her Mammogram Results Were Normal, But Now She’s Fighting...
